UN health agency says hub in South Korea will share mRNA technology being developed by the WHO and partners in South Africa.
The World Health Organization says it has set up a hub in South Korea to train low- and middle-income countries to produce their own vaccines and therapies, and is expanding its COVID-19 vaccine project to a further five nations.
The new hub will share mRNA technology being developed by the WHO and partners in South Africa, where scientists have been working to recreate the COVID-19 vaccine made by Moderna. That effort is taking place without Moderna’s help.
“Vaccines have helped change the course of the COVID-19 pandemic but this scientific triumph has been undermined by vast inequities in access to these life-saving tools,” WHO Director-General Tedros Adhanom Ghebreyesus told a news conference on Wednesday.
“Currently, bio-manufacturing training facilities are located mainly in high-income countries, putting them out of reach for many lower-income countries,” he said.
The new hub outside Seoul will provide workforce training to all countries wishing to produce products such as vaccines, insulin, monoclonal antibodies, Tedros said.
The facility in South Korea was already carrying out training for companies based in the country and will now accommodate trainees from other countries, the WHO said.
The WHO also said five more countries – Bangladesh, Indonesia, Pakistan, Serbia and Vietnam – will receive support from its mRNA technology transfer hub in South Africa.
The countries have been vetted by a group of experts and proved to have the capacity to move to the production stage relatively quickly, the WHO said.
Last week, six African countries – Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia – signed up as the first on the continent to receive the technology to manufacture mRNA vaccines at scale and according to international standards.
On Wednesday, Tedros said that so far 20 countries had expressed interest in getting training on developing an mRNA vaccine by the South African hub.
The WHO said it is currently prioritizing countries that do not have mRNA technology but already have some manufacturing infrastructure and capacity.